Literature DB >> 30500465

Comparison of pyogenic postoperative and native vertebral osteomyelitis.

Uh Jin Kim1, Ji Yun Bae2, Seong-Eun Kim1, Chung-Jong Kim2, Seung-Ji Kang1, Hee-Chang Jang1, Sook In Jung1, Kyoung-Ho Song3, Eu Suk Kim3, Hong Bin Kim3, Wan Beom Park2, Nam Joong Kim4, Kyung-Hwa Park5.   

Abstract

BACKGROUND CONTEXT: Postoperative vertebral osteomyelitis (PVO) after spinal surgery is a clinical challenge. However, there is a paucity of evidence regarding the most likely etiologic organisms to guide the choice of empirical antibiotic therapy, and previous reports of treatment outcomes for PVO are scarce.
PURPOSE: To compare the microbiology, clinical characteristics, and outcomes of pyogenic PVO with native vertebral osteomyelitis (NVO). STUDY
DESIGN: Retrospective comparative study. PATIENT SAMPLE: Patients with microbiologically proven vertebral osteomyelitis from three university-affiliated hospitals in South Korea between January 2005 and December 2015 with follow-up of at least 12 months after completion of antibiotics or until the patient was transferred. Patients who had a spine operation in the same location within 1 year of diagnosis, and all patients with remnant implants at the time of the vertebral osteomyelitis diagnosis, were defined as having PVO. The remainder of the patients was considered to have NVO. Spinal operations included discectomy, laminectomy, arthrodesis, and instrumentation for stabilization of the spine. OUTCOME MEASURES: Overall mortality, neurologic outcomes, treatment failure, and relapse of infection.
METHODS: Demographic data, comorbidities, presenting symptoms, microbiological data, radiographic characteristics, laboratory data (including white blood cell counts, erythrocyte sedimentation rate, and C-reactive protein), surgical treatment, and neurologic outcomes for each patient were reviewed from electronic medical records and analyzed. Mortality rate, treatment failure, and relapse of infection were calculated for the two groups. Factors associated with treatment outcome were evaluated using univariate and multivariate logistic regression analyses.
RESULTS: The study evaluated 104 patients with PVO and 441 patients with NVO. In PVO, the most common isolate was Staphylococcus aureus (34%, n=35), followed by coagulase-negative staphylococci (31%, n=32). In NVO, the most common isolates were S. aureus (47%, n=206) and streptococci (21%, n=94). Of the staphylococci, the proportion of methicillin-resistant strains was significantly higher in PVO than that in NVO (75% vs. 39%, p<.001). The proportion of patients with gram-negative bacilli was 14% in PVO and 20% in NVO. Pre-existing or synchronous nonspinal infection was observed more frequently in NVO than in PVO (33% vs. 13%, p<.001). Although the duration of antibiotic use was similar in both groups, surgery for infection control was performed more frequently in PVO. The mortality rate was similar in both groups. However, the treatment failure and relapse rates at 12 months were higher in the PVO group (23% vs. 13%, p=.009; 14% vs. 7%, p=.028, respectively). Methicillin-resistant S.aureus was significantly associated with treatment failure or relapse via logistic regression (odds ratio 3.01, 95% confidence interval [1.71-5.32], p<.001; odds ratio 2.78, 95% confidence interval [1.40-5.49], p=.003).
CONCLUSIONS: Coverage of methicillin-resistant staphylococci should be considered when prescribing empirical antibiotics for PVO. Although surgery was performed more often in PVO than NVO, the treatment failure and relapse rates at 12 months were higher in PVO.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Microbiology; Outcome; Risk factor; Spinal surgery; Treatment; Vertebral Osteomyelitis

Mesh:

Substances:

Year:  2018        PMID: 30500465     DOI: 10.1016/j.spinee.2018.11.012

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  8 in total

1.  Common infectious diseases of the central nervous system-clinical features and imaging characteristics.

Authors:  Shan Li; Ivy P Nguyen; Kyle Urbanczyk
Journal:  Quant Imaging Med Surg       Date:  2020-12

2.  Can we predict favourable quality of life after surgically treated vertebral osteomyelitis? Analysis of a prospective study.

Authors:  A Yagdiran; C Otto-Lambertz; B Sondermann; A Ernst; D Jochimsen; R Sobottke; J Siewe; P Eysel; N Jung
Journal:  Arch Orthop Trauma Surg       Date:  2022-03-31       Impact factor: 3.067

3.  Microbial Etiology of Pyogenic Vertebral Osteomyelitis According to Patient Characteristics.

Authors:  Dong Youn Kim; Uh Jin Kim; Yohan Yu; Seong-Eun Kim; Seung-Ji Kang; Kang-Il Jun; Chang Kyung Kang; Kyoung-Ho Song; Pyoeng Gyun Choe; Eu Suk Kim; Hong Bin Kim; Hee-Chang Jang; Sook In Jung; Myoung-Don Oh; Kyung-Hwa Park; Nam Joong Kim
Journal:  Open Forum Infect Dis       Date:  2020-05-20       Impact factor: 3.835

4.  Osteomyelitis of the spine: treatments and future directions.

Authors:  Yusuf Mehkri; Patrick Felisma; Eric Panther; Brandon Lucke-Wold
Journal:  Infect Dis Res       Date:  2022-01-24

5.  Anaerobic spondylodiscitis: a retrospective analysis.

Authors:  Chien-Ting Chen; Meng-Huang Wu; Tsung-Yu Huang; Yen-Yao Li; Tsung-Jen Huang; Chien-Yin Lee; Che-Han Lin; Ching-Yu Lee
Journal:  BMC Musculoskelet Disord       Date:  2022-08-17       Impact factor: 2.562

Review 6.  Microbiologic Diagnosis of Pyogenic Spondylitis.

Authors:  Nam Joong Kim
Journal:  Infect Chemother       Date:  2021-06

7.  Comparison anterior minimally invasive oblique retroperitoneal approach and posterior transpedicular approach for debridement fusion in patients with lumbar vertebral osteomyelitis: A randomized controlled trial protocol.

Authors:  Xiang Gao; Shu Wan; Jie Lv; Wei Cheng; Yangbin Zhang
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

8.  Radiographic Features Associated With Increased Surgical Invasiveness in Pyogenic Vertebral Column Osteomyelitis.

Authors:  Tangi Purea; Jeevan Vettivel; Lyn Hunt; Peter G Passias; Joseph F Baker
Journal:  Global Spine J       Date:  2020-06-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.